Xianmei Zhou

Prof. Dr. Xianmei Zhou


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2023 in Phytomedicine
Verified
Journal Article
Closed access
DHDi Han
Di Han
HGHaiying Gong
Haiying Gong
YWYun Wei
Yun Wei
YXYong Xu
Yong Xu
XZXianmei Zhou
Xianmei Zhou
FFFanchao Feng
Fanchao Feng

15 May 2019 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
FFFanchao Fen
Fanchao Fen
JZJiarui Zhang
Jiarui Zhang
ZWZhichao Wang
Zhichao Wang
QWQi Wu
Qi Wu
XZXianmei Zhou
Xianmei Zhou
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease with poor prognosis and limited treatment options. N‑acetylcysteine (NAC), an anti‑oxidant drug, has promising potential in the treatment of IPF. In the present systematic review and meta‑analysis, the efficacy and safety of NAC for IPF were investigated. The following databases were comprehensively searched for relevant studies published until August 2018: Pubmed, Embase, Cochrane library, Chinese National Knowledge Infrastructure, Wangfang Database, VIP and the Chinese Biology Medical Database. A total of 21 controlled trials assessing the efficacy and safety of NAC therapy for IPF were identified and primary outcomes [forced vital capacity (FVC), adverse side effects] and secondary outcomes [diffusing capacity for carbon monoxide (DLCO) and its percentage predicted value (DLCO%), vital capacity (VC), partial arterial oxygen pressure (PaO2), 6‑min walking distance test and mortality] were extracted for the meta‑analysis. The risk ratio and mean difference or standardized mean difference with 95% confidence interval were calculated using RevMan 5.3 software. Analysis of the pooled data revealed that, compared with control treatments (routine treatment or drugs other than anti‑oxidants), NAC therapy reduced the decline in lung function, as indicated by the FVC and DLCO, and slowed the progression of the disease, as indicated by the PaO2, while complications and mortality were similar. These results suggest good efficacy, tolerability and safety of the treatment. Furthermore, subgroup analysis revealed that combined therapy including NAC for IPF might be more effective than NAC monotherapy, while oral administration of NAC was safer than inhalation. In conclusion, the results of the present review and meta‑analysis provide important information that may serve as a guide regarding NAC therapy for IPF in clinical practice.

29 May 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HFHai-Jian Fu
Hai-Jian Fu
YZYu-Ren Zhou
Yu-Ren Zhou
BBBeihua Bao
Beihua Bao
MJMeng-Xuan Jia
Meng-Xuan Jia
YZYang Zhao
Yang Zhao
XZXianmei Zhou
Xianmei Zhou

1 April 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
FFFanchao Feng
Fanchao Feng
ZWZhichao Wang
Zhichao Wang
RLRuofei Li
Ruofei Li
QWQi Wu
Qi Wu
CGCheng Gu
Cheng Gu
HHHailang He
Hailang He
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease with a poor prognosis and limited treatment options. The incidence of IPF increases with age, and the mechanisms related to aging such as cellular senescence have been strongly implicated in disease pathology. Therefore, a better understanding of fibroblasts senescence might provide a new therapeutic strategy to prevent and treat pulmonary fibrosis. In this study, we aimed to explore the effects of citrus alkaline extracts (CAE) on the fibroblasts senescence, and elucidate the underlying mechanism to ameliorate pulmonary fibrosis. We demonstrated that CAE mitigated the collagen deposition by the initial early treatment, suggesting a potential preventive effect of CAE on pulmonary fibrosis. The expression of senescence biomarkers P16INK4a and P21, concomitant with down-regulation of the myofibroblasts marker α-SMA, and the number of senescence-associated β-galactosidase (SA-β-Gal) positive cells were decreased by CAE treatment, indicating a significant inhibitory effect of CAE on fibroblast senescence. Additionally, CAE down-regulated the expression of the senescence-associated secretory phenotype (SASP) in etoposide-induced senescent fibroblasts. Further studies indicated that COX-2 activation was required for CAE to inhibit the lung fibroblast senescence through a P53-dependent pathway. Results showed that the anti-senescence effect of CAE was abrogated when COX-2 was knocked down or inhibited by COX-2 inhibitor NS-398 or indomethacin in lung fibroblasts. Meanwhile, the anti-fibrotic and anti-senescence effect of CAE were abolished due to disruption of COX-2 in vivo. Collectively, our results provided a novel insight into the potential mechanism of CAE to inhibit the fibroblasts activation through preventing cellular senescence.

6 July 2022 in Phytomedicine
Verified
Journal Article
Closed access
DWDan Wang
Dan Wang
YXYong Xu
Yong Xu
THTongxing Huang
Tongxing Huang
WPWenpan Peng
Wenpan Peng
DZDongwei Zhu
Dongwei Zhu
QWQi Wu
Qi Wu

25 May 2022 in Phytomedicine
Verified
Journal Article
Closed access
YXYong Xu
Yong Xu
XWXuan Wang
Xuan Wang
DHDi Han
Di Han
JWJunyi Wang
Junyi Wang
ZLZichen Luo
Zichen Luo
JSJinjun Shan
Jinjun Shan